Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2010 - 2026)
Gyre Therapeutics (GYRE) reported Net Income towards Common Stockholders of -$8.7 million for Q1 2026, down 422.13% year-over-year from $2.7 million in Q1 2025, and down 404.41% on a QoQ basis from -$1.7 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$8.7 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 422.13% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.4 million (down 187.74% YoY) and the FY2025 annual result came in at $5.0 million, down 58.4% from the prior year.
- Net Income towards Common Stockholders declined to -$8.7 million in Q1 2026 per GYRE's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $51.6 million in Q2 2022 and bottomed at -$101.0 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is $1.1 million (2024), against an average of -$4.8 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders surged 359.09%; it then tumbled 1640.4% in 2025.
- Tracing GYRE's Net Income towards Common Stockholders over 5 years: stood at -$29.9 million in 2022, then sank by 237.7% to -$101.0 million in 2023, then surged by 99.9% to -$99000.0 in 2024, then plunged by 1640.4% to -$1.7 million in 2025, then tumbled by 404.41% to -$8.7 million in 2026.
- Per Business Quant, the three latest GYRE Net Income towards Common Stockholders figures stand at -$8.7 million (Q1 2026), -$1.7 million (Q4 2025), and $3.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.69 Mn |
| Dec 31, 2025 | -1.72 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 442,000.00 |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | -99,000.00 |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 7.53 Mn |
| Dec 31, 2023 | -101.01 Mn |
| Sep 30, 2023 | 3.98 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | -29.91 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.24 Mn |
| Jun 30, 2021 | -19.93 Mn |
| Mar 31, 2021 | -22.44 Mn |
| Dec 31, 2020 | -18.91 Mn |
| Sep 30, 2020 | -16.03 Mn |
| Jun 30, 2020 | -17.25 Mn |
| Mar 31, 2020 | -4.05 Mn |
| Dec 31, 2019 | -13.61 Mn |
| Sep 30, 2019 | -12.71 Mn |
| Jun 30, 2019 | -13.78 Mn |
| Mar 31, 2019 | -15.08 Mn |
| Dec 31, 2018 | -10.84 Mn |
| Sep 30, 2018 | -7.69 Mn |
| Jun 30, 2018 | -6.48 Mn |
| Mar 31, 2018 | -5.04 Mn |
| Dec 31, 2017 | -5.75 Mn |
| Sep 30, 2017 | -5.79 Mn |
| Jun 30, 2017 | -9.83 Mn |
| Mar 31, 2017 | -4.14 Mn |
| Dec 31, 2016 | -3.75 Mn |
| Sep 30, 2016 | -4.77 Mn |
| Jun 30, 2016 | -4.83 Mn |
| Mar 31, 2016 | -3.59 Mn |
| Dec 31, 2015 | -6.51 Mn |
| Sep 30, 2015 | -3.61 Mn |
| Jun 30, 2015 | -4.34 Mn |
| Mar 31, 2015 | -6.75 Mn |
| Dec 31, 2014 | -4.56 Mn |
| Sep 30, 2014 | -4.86 Mn |
| Jun 30, 2014 | -8.14 Mn |
| Mar 31, 2014 | -15.00 Mn |
| Dec 31, 2013 | -13.36 Mn |
| Sep 30, 2013 | -12.90 Mn |
| Jun 30, 2013 | -12.37 Mn |
| Mar 31, 2013 | -8.07 Mn |
| Dec 31, 2012 | -16.03 Mn |
| Sep 30, 2012 | -7.88 Mn |
| Jun 30, 2012 | 14.49 Mn |
| Mar 31, 2012 | 2.26 Mn |
| Dec 31, 2011 | -9.81 Mn |
| Sep 30, 2011 | -9.05 Mn |
| Jun 30, 2011 | -2.26 Mn |
| Mar 31, 2011 | 12.59 Mn |
| Dec 31, 2010 | -2.16 Mn |
| Sep 30, 2010 | 2.49 Mn |
| Jun 30, 2010 | 3.78 Mn |